Targeting Drug Memories With Methylphenidate
Study Details
Study Description
Brief Summary
This study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. In this fMRI study with a within-subjects placebo-controlled double-blind cross-over design, oral methylphenidate (20 mg) or placebo will be administered to individuals with cocaine use disorders (CUD) to peak during the retrieval of a drug-cue memory before extinction; in addition to fMRI activations, skin conductance responses (SCR, acquired simultaneously) will serve as the psychophysiological indicators of memory modification. Assessments of interference with the return of drug-cue memories via SCR and craving will be conducted the day following MRI. This pharmocologically-enhanced behavioral approach to decreasing drug memories and craving in iCUD could ultimately be used to develop effective cue-exposure therapies for drug addiction. Procedures include MRI, blood draw, questionnaires and interviews, skin conductance response measures, and behavioral tasks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Early Phase 1 |
Detailed Description
Cue-exposure therapy has not proven efficacious in reducing relapse in drug addiction, illuminating the need for alternative strategies. Here researchers will test the neural correlates of two strategies, encompassing behavioral and pharmacological approaches, aimed to interfere with the return of drug memories in individuals with cocaine use disorders. Results may pave the way towards enhancing the efficacy of cue-exposure therapy in reducing cue-induced craving and relapse in drug addiction (generalizable across drugs of abuse/behavioral addictions).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Methylphenidate then Placebo 20 mg of methylphenidate then matching placebo pill. |
Drug: Methylphenidate
Oral administration of 20 mg Methylphenidate
Behavioral: Memory reconsolidation
Retrieval of drug-cue memories before extinction.
Drug: Placebo
Matching placebo pill
|
| Placebo Comparator: Placebo then Methylphenidate Matching placebo pill then 20 mg of methylphenidate. |
Drug: Methylphenidate
Oral administration of 20 mg Methylphenidate
Behavioral: Memory reconsolidation
Retrieval of drug-cue memories before extinction.
Drug: Placebo
Matching placebo pill
|
Outcome Measures
Primary Outcome Measures
- fMRI blood-oxygenation level dependent (BOLD) signal [Day 1]
fMRI blood-oxygenation level dependent (BOLD) signal deactivation in the ventromedial prefrontal cortex in response to retrieval of drug-cue memory.
- fMRI blood-oxygenation level dependent (BOLD) signal [Day 7]
fMRI blood-oxygenation level dependent (BOLD) signal deactivation in the ventromedial prefrontal cortex in response to retrieval of drug-cue memory.
Secondary Outcome Measures
- Skin Conductance Responses (SCR) [24 hours after each neuroimaging session]
Measure of changes to skin conductance responses in response to retrieval of drug-cue memory. The conductance is measured by placing two electrodes on the fingers and passing a small, 0.5 V electric charge between the two points. An increase in the skin conductance response (SCR) reflects heightened arousal in response to the drug-cue memory, changes in which are monitored following exposure to the drug cues.
- Craving [24 hours after each neuroimaging session]
Measure of changes to craving in response to retrieval of drug-cue memory. Self-reported cue-induced craving in response to drug cues will be assessed.
Eligibility Criteria
Criteria
Inclusion criteria:
-
Ability to understand and give informed consent
-
Males and females 26-50 years of age
-
DSM-V diagnosis for CUD or otherwise problematic cocaine use as clinically determined
Exclusion criteria:
-
DSM-5 diagnosis for schizophrenia or developmental disorder (e.g., autism)
-
Head trauma with loss of consciousness
-
History of neurological disease of central origin including seizures
-
Cardiovascular disease including high blood pressure and/or other medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, and infectious diseases including Hepatitis B and C or HIV/AIDS
-
Metal implants or other MR contraindications
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Icahn School of Medicine at Mount Sinai | New York | New York | United States | 10029 |
Sponsors and Collaborators
- Icahn School of Medicine at Mount Sinai
- National Institute on Drug Abuse (NIDA)
Investigators
- Principal Investigator: Rita Z Goldstein, PhD, Icahn School of Medicine at Mount Sinai
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GCO 20-2707
- R21DA054281